Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
31 October, 2014 14:30 IST
Dr Reddys gets USFDA nod for Sildenafil tablets
Source: IRIS | 19 Nov, 2012, 09.43AM
Comments  |  Post Comment

Dr Reddys Laboratories, an integrated global pharmaceutical company,  announced that it has launched Sildenafil tablets (20 mg), a bioequivalent generic version of Revatio (Sildenafil) tablets in the US market.

It has received approval by the United States Food & Drugs Administration (USFDA) for ANDA Sildenafil tablets.

The Revatio brand had US sales of approximately USD 338.67 million for the most recent 12 months ending September 2012 according to IMS health.

Shares of the company gained Rs 16, or 0.91%, to trade at Rs 1,773.35. The total volume of shares traded was 755 at the BSE (9.32 a.m., Monday).

Dr Reddy`S Laboratories Limited   (Q,N,C,F)*

Live News
M&M Q2 in-line; profit falls 4.3% - 31-Oct-2014 14:06
RBI sets rupee reference rate at 61.40 against dollar - 31-Oct-2014 14:04
European stocks trade higher as Japan boosts stimulus - 31-Oct-2014 14:01
Sensex surges 377 points; metal, capital goods lead - 31-Oct-2014 13:51
Whirlpool jumps on strong Q2 result - 31-Oct-2014 13:43
Useful tips for first time credit card users - 31-Oct-2014 13:37
India's water reservoir levels at 74% capacity last week - 31-Oct-2014 12:52
Sensex, Nifty at record breaking spree in noon trade - 31-Oct-2014 12:51
Union Bank of India gains after good Q2 earnings - 31-Oct-2014 12:39
Union Bank of India Q2 profit jumps 78.4%, missing estimates - 31-Oct-2014 12:32
India VIX moves up in noon trade - 31-Oct-2014 12:31
* Q - Quote , N - News , C - Chart , F - Financials
Comments Post comment 
 Post Comment
Name Email
Security Code type   nwh3qd into this box
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer